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Summary
Objectives: The Psychology Task Force of the Medical Therapies Commission 
of the International League Against Epilepsy (ILAE) has been charged with tak-
ing steps to improve global mental health care for people with epilepsy. This study 
aimed to inform the direction and priorities of the Task Force by examining epilepsy 
healthcare providers’ current practical experiences, barriers, and unmet needs around 
addressing depression and anxiety in their patients.
Methods: A voluntary 27-item online survey was distributed via ILAE chapters and 
networks. It assessed practices in the areas of screening, referral, management, and 
psychological care for depression and anxiety. A total of 445 participants, from 67 
countries (68% high income), commenced the survey, with 87% completing all com-
ponents. Most respondents (80%) were either neurologists or epileptologists.
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1 |  INTRODUCTION
The prevalence of mental health comorbidities, particularly de-
pression and anxiety, in people with epilepsy (PWE) is high 
and associated with suboptimal patient outcomes,1,2 such as 
reduced quality of life,3 pharmacoresistant seizures,4 suicide,5 
injuries,6 and medication nonadherence.7 To comprehensively 
manage epilepsy and improve quality of life, both behavioral 
and seizure specific outcomes need to be addressed.8 Increasing 
awareness of the importance of and morbidity from mental 
health comorbidities in epilepsy has resulted in International 
League Against Epilepsy (ILAE) consensus statements by 
the ILAE Commission on the Neuropsychiatric Aspects of 
Epilepsy, and the Neuropsychobiology Commission,9,10 and 
recommendations of the inclusion of routine screening for 
depression and anxiety in PWE according to the American 
Academy of Neurology’s quality indicators.11,12 It is also now 
strongly encouraged that depression and anxiety should either 
be treated by epilepsy healthcare professionals or they should 
be referred for appropriate external management.13
It remains unknown to what extent these recommendations 
and quality indicators have been adopted in clinical prac-
tice.14–16 For instance, a survey of 102 epileptologists in the 
United States found that less than half routinely screened for 
anxiety and that only 5% utilized a validated screening mea-
sure.17 Moreover, there is currently little international consen-
sus about what role neurologists, epileptologists, and other 
epilepsy healthcare professionals should play in the man-
agement of mental health comorbidities, and no systematic 
approaches or protocols have been developed in this area.13 
However, the recently launched ILAE roadmap for a compe-
tency-based educational curriculum includes the appropriate 
management of psychiatric emergencies (eg, suicidal ide-
ation) and recognition of when to refer patients for treatment 
of mental health comorbidities as key competencies for epi-
leptologists.18 This highlights the need to better examine the 
existing clinical landscape and determine what barriers exist 
to the management of mental health comorbidities in PWE.
The ILAE Psychology Task Force of the Medical 
Therapies Commission has been charged with improving 
Results: Less than half of respondents felt adequately resourced to manage depres-
sion and anxiety. There was a lack of consensus about which health professionals 
were responsible for screening and management of these comorbidities. About a third 
only assessed for depression and anxiety following spontaneous report and lack of 
time was a common barrier (>50%). Routine referrals to psychiatrists (>55%) and 
psychologists (>41%) were common, but approximately one third relied on watchful 
waiting. A lack of both trained mental health specialists (>55%) and standardized 
procedures (>38%) was common barriers to referral practices. The majority (>75%) 
of respondents’ patients identified with depression or anxiety had previously accessed 
psychotropic medications or psychological treatments. However, multiple barriers to 
psychological treatments were endorsed, including accessibility difficulties (52%).
Significance: The findings suggest that while the importance of managing depression 
and anxiety in patients with epilepsy is being recognized, there are ongoing barriers to 
effective mental health care. Key future directions include the need for updated protocols 
in this area and the integration of mental health professionals within epilepsy settings.
K E Y W O R D S
mental health, psychiatric comorbidity, psychotherapy, screening, suicide, treatment
Key Points
• ILAE survey of epilepsy health professional’s 
screening, referral, and management practices for 
depression and anxiety.
• Less than half felt adequately resourced to man-
age these comorbidities.
• Lack of consensus about which health professionals 
were responsible for screening and management.
• Ongoing barriers to mental health care, includ-
ing a lack of trained mental health specialists and 
standardized procedures.
• Future directions include need for updated proto-
cols and the integration of mental health profes-
sionals within epilepsy settings.
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mental health care for PWE. To that end, this study aimed to 
inform the future direction and priorities of the Task Force by 
examining epilepsy healthcare professionals’ current practi-
cal experiences, barriers, and unmet needs in relation to the 
screening, referral, and management of depression and anx-
iety in their PWE. We also aimed to examine differences in 
practice by low-, medium-, and high-income countries.
2 |  METHOD
2.1 | Procedure and materials
The ILAE Psychology Task Force developed an online sur-
vey. Six items were adopted, with permission, from a pre-
vious US survey of neurologist members of the American 
Epilepsy Society,14 and additional items following a review 
of the relevant literature. The survey consisted of 27 closed 
items, which included questions about 1. Professional train-
ing and epilepsy expertise (11 items); 2. Screening proce-
dures (8 items); 3. Referral options (4 items); 4. Available 
treatments (2 items); 5. Access to psychological care (1 item); 
and 6. Requests for future services by the ILAE Psychology 
Task Force (1 item). A copy of the survey is included as a 
Appendix S1—Survey. At the end of the survey, participants 
were provided with a link to the ILAE Psychology Task Force 
Web site (www.ilae.org/patie nt-care/menta l-healt h-care-re-
sou rces), which contains resources about mental health care 
in epilepsy. The survey was reviewed by ILAE Psychiatry 
Commission members and approved for use and distribution 
to members by the ILAE Executive Committee.
The survey was piloted among epilepsy health profession-
als practicing in Australia. In order to reach these profession-
als, the Epilepsy Society of Australia (the Australian Chapter 
of the ILAE) emailed its members with an invitation and link 
to the survey. Recruitment took place between November 
2018 and December 2018; two reminder emails were sent 
during this time. Following this successful acceptability pilot, 
the survey was opened internationally. No major changes 
were made. The survey was circulated via the ILAE Regional 
Chairs, who were asked to forward the questionnaires to in-
dividual ILAE Chapters for distribution. The survey was also 
promoted on the Web site for the 33rd International Epilepsy 
Conference in Bangkok (2019). The international survey re-
mained open from April 2019 to December 2019.
Participants were invited to take part in the survey by 
means of an email including a secure link to a Qualtrics 
survey. This link directed potential participants to an infor-
mation statement and consent form before they were able to 
proceed to the first item. The questionnaire was designed to 
take no more than 10-15 minutes to complete.
Participants were eligible if they were (a) At least 18 
years of age; (b) A professional working with patients with 
neurological disorders; (c) Had competence in English; 
and (d) Provided consent. The survey was approved by the 
Macquarie University Human Research Ethics Committee.
2.2 | Statistical analyses
Descriptive statistics were utilized to examine rates of en-
dorsement on the survey items. Chi-square analyses were 
used to analyze significant differences between low/middle-
income countries with high-income countries19 on questions 
with forced option responses. For comparison purposes, low- 
and middle-income countries were collapsed into one group 
(low/middle income). IBM SPSS Statistics program 24 was 
used for analyses.
3 |  RESULTS
Of the 445 participants who commenced the survey, 388 
(87.2%) completed it in its entirety. Respondents reflected 
participation from 67 countries (displayed in Table S1). 
According to World Bank classifications,19 most partici-
pants were from high income (n = 304; 68.3%), followed by 
middle-income (n = 106; 23.82%) and low-income countries 
(n = 35; 7.87 %). The countries with the highest number of 
participants included Brazil (n = 52), Australia (n = 52), Italy 
(n = 35), and Germany (n = 33).
3.1 | Health professionals’ training and 
experience with epilepsy
As displayed in Table 1, most respondents were neurolo-
gists (n = 204; 46%) or epileptologists (n = 149; 33.6%) with 
the majority working in public hospitals (n  =  180; 42.3%) 
and university healthcare systems (n  =  121; 28.3%). Most 
respondents were fully trained (n = 393; 87.9%) and consid-
ered themselves an expert in epilepsy management (n = 224; 
50.1%).
3.2 | Depression and anxiety management
3.2.1 | Importance and resources 
for management
The vast majority (≥93%) of respondents indicated they 
“strongly agree” or “agree” that the management of de-
pression and anxiety is integral to the comprehensive care 
of PWE. However, only 40% “strongly agree” or “agree” 
that their setting is adequately resourced to manage these 
mental health comorbidities.
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3.2.2 | Responsibility for 
screening and management
Most respondents believed that neurologists/epileptolo-
gists (n = 221; 54.3%) should be responsible for screening 
for depression or anxiety in PWE, followed by general/
family practitioners (n  =  75; 18.4%; Figure 1). Just over 
a third thought neurologists/epileptologists (n  =  150/420, 
35.7%) should take primary responsibility for organizing 
the management of anxiety and depression, followed by 
T A B L E  1  Characteristics of respondents










Social worker 5 (1.1)
Special professional interest in epilepsy 442
Yes 425 (96.3)
No 17 (3.8)
Level of training in profession 443
Fully trained (eg, attending) 393 (87.9)
In training (eg, intern, resident, fellow, postdoc) 50 (11.2)
Level of experience managing epilepsy 431
Expert (>10 y) 224 (50.1)
Advanced (5-10 y) 102 (22.8)
Novice (<5 y) 105 (23.5)
Primary patient groupa 431
Children (0-18 y) 167 (38.7)
Adults (18-65 y) 304 (70.5)
Older adults (>65 y) 143 (33.2)
Patients with intellectual disability 138 (32)
Percentage of patients who have epilepsy 427
<10% 32 (7.5)
>10% and <30% 94 (22)
>30% and <50% 60 (14.1)
>50% and <70% 98 (23)
>70% and <90% 63 (14.8)
>90% to 100% 80 (18.7)
Primary setting for working with PWE 427
University Health Care System 121 (28.3)
Public Hospital 180 (42.3)
Private Hospital 52 (12.2)
Private Practice 30 (7.0)
Community Health Care Service 21 (4.9)
Other 23 (5.4)
aResponses were not mutually exclusive, and participants could select more than one. 
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psychiatrists (n  =  106, 25.2%), psychologists/neuropsy-
chologists (n  =  84, 20%) general/family practitioners 
(n = 64, 15.2%), and epilepsy or psychiatry nurse special-
ists (n = 16; 3.8).
3.2.3 | Screening / assessment practices
As displayed in Figure 2, screening practices for depression 
and anxiety were almost identical. Over 40% of respondents 
indicated they assessed for both comorbidities at every pa-
tient visit (ie, initially and at every follow-up). About one 
third based screening for depression (n  =  114; 28%) and 
anxiety (n = 123; 30.7%) on spontaneous reports by the pa-
tient or a relative. In contrast, 58% (n = 231) only screened 
for suicidality if symptoms were spontaneously reported, and 
about 6% (n = 25) never screened suicidality. Most respond-
ents reported that they included screening questions as part of 
their clinical interview for depression and anxiety (≥75.6%). 
Fewer stated that they used a validated screening instrument 
(≥23.3%) or delegated the use of a validated screening instru-
ment to other staff (≥8.1%).
3.2.4 | Barriers to screening
Over half of respondents reported a lack of time during 
clinic visits was a barrier to screening practices for both 
depression (n = 217; 54.1%) and anxiety (n = 203; 50.9%; 
Table 2). Other frequently reported barriers included lack 
of access to psychiatric / psychological treatment resources 
(≥19.3%) and uncertainty about appropriate screening in-
struments (≥17%). Over 20% of respondents reported 
experiencing no barriers to screening and management for 
anxiety and depression.
3.3 | Referral practices and barriers
Respondents endorsed the following referral patterns: 
referral to a psychiatrist for both depression and anxiety 
(≥55.6%), followed by referral to a psychologist (≥41.5%). 
Less commonly, patients were started on psychotropic 
medication (≥33.8%) or subjected to monitoring (“watchful 
waiting”; ≥26.9%; Table 3). The most commonly endorsed 
barriers to referring patients on for follow-up assessment/
management included lack of mental health specialists 
trained to assess and manage PWE (≥55.4%), standardized 
assessment procedures (≥37.8%), and time to deal with the 
referral procedures (≥29%).
3.4 | Treatments accessed and 
psychological care
The majority of respondents had patients who had accessed 
both psychological treatments with mental health profes-
sionals (≥78.3) and psychotropic medications (≥74.7%) 
at some stage. Other common interventions included an-
tiseizure medication (ASM) changes (≥66.3%) and psy-
choeducation (≥43.4%; see Table 4). The most common 
barrier was a lack of appropriately trained mental health 
specialists (n = 234; 60%), followed by patients’ inability 
to access treatment (n  =  204; 52.3%) and lack of desire 
for psychological therapy (n = 197; 50.5%). An additional 
barrier reported was that intellectual/cognitive difficulties 
F I G U R E  1  Clinicians believed responsible for the organization of the screening and management for depression and anxiety of patients with 
epilepsy.
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limit the benefits of psychological treatment for PWE 
(n=160; 41%; see Table 4).
3.5 | The ILAE psychology task force’s role
A majority of respondents felt the ILAE Psychology Task 
Force should create guidelines for referring/managing de-
pression/anxiety in PWE (n = 311; 80.2%), followed by the 
provision of epilepsy educational resources for mental health 
professionals (n = 270; 69.6%), creation of registries of men-
tal health professionals specializing in epilepsy (n  =  265; 
68.3%), and lastly the provision of mental health educational 
resources for neurologists (n = 244; 62.9%).
3.6 | Comparison between responses from 
low/middle-, and high-income countries
No significant differences among countries were ob-
served in relation to importance of and resources for the 
management of depression and anxiety or screening prac-
tices. However, there were significant differences in who 
was believed to be responsible for screening (χ2 = 22.72, 
P  <  0.001) and management of anxiety and depression 
(χ2  =  16.89, P  <  0.001). Specifically, more respond-
ents from low/middle-income than high-income coun-
tries considered a psychiatrist responsible for screening 
(n  = 15/132; 11.36% vs n  =  4/275; 1.5%). However, the 
endorsed responsibility for neurologists/ epileptologists 
for mental health screening was very similar between low/
middle-income and high-income countries (n  =  74/132; 
56.1% vs n = 147/275; 53.5%).
In addition, fewer respondents from low/middle-income 
than high-income countries considered a GP responsible for 
the management of depression and anxiety in PWE (11/137; 
8% vs 53/283; 18.7%). However, endorsement of the role of 
neurologists/ epileptologists in the context of management of 
mental health comorbidities was similar between low/middle 
(n = 54/137; 39.4%) and high-income countries (n = 96/283; 
33.9%).
4 |  DISCUSSION
The ILAE Psychology Task Force has been charged with im-
proving mental health care for PWE. This survey aimed to 
inform the future direction and priorities of the Task Force 
by exploring the current clinical practices of epilepsy health-
care professionals across the globe, through ILAE chapters, 
in the management of depression and anxiety in their patients 
with epilepsy. Encouragingly, almost all survey respondents 
(87%) believed the management of both depression and anxi-
ety was integral to epilepsy care. However, less than half felt 
they were adequately resourced to manage these comorbidi-
ties themselves. The survey responses uncovered key trends 
and barriers in relation to the responsibilities and manage-
ment practices (eg, screening, referral, psychological care) 
for mental health comorbidities and highlighted several im-
portant areas for future consideration.
Despite increasing calls by international experts and 
multidisciplinary ILAE Task Forces for neurologists/epi-
leptologists to increase their responsibility for the screen-
ing and management of mental health symptoms in their 
patients,8,17 there were large discrepancies in who should 
have the primary responsibility to do so in clinical practice. 
While more than half the sample believed it was the role of 
the neurologist/epileptologist to screen for mental health 
comorbidities, only one third believed either a neurologist 
(20%) or epileptologist (16%) was responsible for organiz-
ing management. Five percent believed psychiatrists should 
screen for mental health comorbidities, with slightly more 
acknowledgment of the role of psychiatrists in screening 
from participants in low/middle-income countries. These 
F I G U R E  2  Frequency of screening practices
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findings may suggest there is some misconception about 
the role of psychiatrists given psychiatrists are trained 
to diagnose not screen mental health comorbidities and 
screening is typically the responsibility of all other health 
professionals. If a screen is positive, a provider will ideally 
refer to a mental health professional who makes a definite 
diagnosis as a valid basis for treatment initiation. However, 
in areas where resources are not as intense, an epilepsy 
healthcare professional may have to take on the role of more 
assessment to determine whether a diagnosis is warranted. 
Interestingly, respondents rarely endorsed neuropsycholo-
gists as having a role in the management (7%) or screening 
(4%) of depression and anxiety. Neuropsychologists in ep-
ilepsy centers are typically employed to conduct compre-
hensive evaluations of PWE20 but do not treat depression 
or anxiety, despite some recognition within the discipline 
they are ideally situated to do so.21 More commonly the as-
sessment and management of mental health comorbidities 
from providers other than neurologists/epileptologists in-
volves clinical psychologists, psychiatrists, or general prac-
titioners. Taken together, it appears there is a lack of clarity 
about the roles of neurologists/epileptologists and other 
health professionals in the management of mental health 
comorbidities of epilepsy, which likely vary by countries 
and resources.
In relation to the frequency of screening for both de-
pression and anxiety, very few respondents never screened, 
and over 40% screened at the initial and every follow-up 
visit, as suggested by the 2017 AAN quality measurement 
guidelines.11,12 However, screening only following spon-
taneous reporting of symptoms was also high, in particu-
lar in the case of suicidal ideation (58%). This finding is 
very concerning given that patients typically underdisclose 
symptoms of depression to their physicians,22 with more 
depressive symptoms leading to reduced odds of patients 
disclosing.23,24 Moreover, the risk of death by suicide in 
PWE is three times higher than the general population25 
and an increased risk of suicide has been found among 
PWE with no recorded psychiatric diagnosis history.26 
Therefore, screening for suicidal ideation is strongly rec-
ommended9 and managing suicidal ideation is a key com-
petency area of the new ILAE educational roadmap for 
epileptologists. Of note, very few respondents (<10%) re-
ported that they experienced any discomfort or uncertainty 
when asking about suicidality as a barrier to screening for 
depression. Thus, it remains unclear why routine screening 
for suicidal ideation is so low, illustrating that further work 
is needed in this area.
In relation to screening methods, most respondents in-
corporated screening questions into their clinical interview. 





Method of screeninga 407 401
I include screening question(s) as part of my clinical interview 307 (75.6) 304 (76.0)
I administer/score validated screening instrument 114 (28.0) 93 (23.3)
Other clinic staff administer/ score validated screening instrument 33 (8.1) 35 (8.8)
Other 40 (9.9) 41 (10.2)
Barriers to screeninga 401 399
Lack of time during clinic visit 217 (54.1) 203 (50.9)
There are no accessible psychiatric/psychological treatment resources in setting 81 (20.2) 77 (19.3)
Uncertainty about appropriate screening instruments 69 (17.2) 84 (21.1)
Uncertainty about where to refer patients for treatment, if dep/anx identified 59 (14.7) 58 (14.5)
Treatment of dep/anx is not part of my role in the management of PWE 53 (13.2) 56 (14.0)
Allowing patients to initiate concerns first 52 (13.0) 49 (12.3)
Uncertainty about the treatment of dep/anx 37 (9.2) 51 (12.8)
Addressing dep/anx was not part of training 46 (11.5) 40 (10.0)
Inaccessibility to appropriate screening instruments 40 (10) 42 (10.5)
Discomfort or uncertainty with suicidal ideation 37 (9.2) -
Discomfort or uncertainty about initiating discussions about dep/anx 22 (5.5) 20 (5.0)
Assessing dep/anx is not part of my role in the management of PWE 19 (4.7) 23 (5.8)
No barriers 82 (20.4) 88 (22.1)
Abbreviations: anx, anxiety; dep, depression; PWE, patients with epilepsy.
aResponses were not mutually exclusive, and participants could select more than one. 
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However, it is an important limitation of this survey that the 
adequacy of these questions was not assessed qualitatively. 
Mental health assessment involves asking patients about 
specific symptoms of anxiety and depression, as opposed 
to simply asking “are you depressed or anxious,” which 
can underestimate endorsement, and thus prevalence.13 For 
PWE, it is also important to distinguish between cognitive 
and somatic symptoms of these disorders and overlap with 
seizure phenomena and ASM side effects.27 A recent me-
ta-analysis found that the rate of anxiety disorders in studies 
relying on clinical judgment was only 8%, compared with 
27% among studies utilizing a structured or validated clin-
ical interview.28 Approximately only a third of respondents 
in the current study used validated screening instruments to 
screen for depression and anxiety, with screening practices 
almost identical for these two comorbidities. Consistent 
with previous surveys,14,29 lack of time was the most signif-
icant barrier for screening for both depression and anxiety. 
Additional barriers included lack of accessible psychiatric/
psychological treatment resources for depression and uncer-
tainty about screening devices for anxiety. There have been 
significant efforts to develop, translate, and promote the use 
of the epilepsy-specific depression screening instrument, 
such as the Neurological Disorders Depression Inventory 
for Epilepsy10,30 which serves as an excellent suicidality 
screening instrument.31 In 2019, an epilepsy-specific anx-
iety screening was published (the Brief Epilepsy Anxiety 
Screening Instrument),32 which may aid in screening.
The most common typical next step once PWE were 
identified with depressive and/or anxiety symptoms was a 
referral to psychiatrist (>55%) followed by a psychologist 
(>41%). Unfortunately, psychiatrists and clinical psycholo-
gists seldom form part of interdisciplinary epilepsy teams.33 
As a result, it may not be surprising that one third reported 
placing patients on psychotropic medications. However, it re-
mains unclear why another third (>26%) endorsed watchful 
waiting. Notably, watchful waiting is not recommended10 and 
suggests an underestimation of the need to initiate treatment 
of mental health comorbidities. Anecdotal evidence suggests 
that some neurologists/epileptologists may interpret symp-
toms of depression and anxiety as the logical consequence 
of the burden of epilepsy in severely affected patients rather 
than a mental health comorbidities requiring or amenable via 
specific intervention. Compared to a prior study in which 
anxiety was screened and managed less often than depres-






Typical next steps when identified with depression/
anxietya 
398 394
Refer patients to a psychiatrist 254 (63.8) 219 (55.6)
Refer patients to a psychologist 165 (41.5) 174 (44.2)
Place patients on psychotropic medications 139 (34.9) 133 (33.8)
Monitor (watchful waiting) 107 (26.9) 117 (29.7)
Refer patients to a psychotherapist 96 (24.1) 95 (24.1)
Refer patients back to primary health practitioner 89 (22.4) 90 (22.8)
Provide literature on mental health 58 (14.6) 63 (166)
Suggest patients seek help themselves 65 (16.3) 54 (13.7)
Barriers to follow-up assessment and managementa 397 392
Lack of mental health specialists trained to assess/
manage PWE
219 (55.2) 217 (55.4)
No standardized procedures around these issues in 
place of practice
150 (37.8) 148 (37.8)
Lack of time to deal with the referral procedures 115 (29.0) 116 (29.6)
Limited funding for referral procedures 70 (17.6) 78 (19.9)
Referrals for follow-up is the role of other 
services (eg, epilepsy advocacy groups, general 
practitioner)
40 (10.1) 34 (8.7)
No barriers 76 (19.1) 76 (19.4)
Other 23 (5.8) 22 (5.6)
aResponses were not mutually exclusive, and participants could select more than one. 
T A B L E  3  Referral practices and 
barriers for depression and anxiety
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in PWE is becoming more widely recognized, as at least 
equivalent to that of depression. Unfortunately, significant 
barriers to treatment for mental health comorbidities are the 
lack of standardized procedures around referral practices and 
the inability to identify or uncertainty for when to refer PWE 
for psychological treatment. The last consensus on clinical 
practice statements for the treatment of neuropsychiatric con-
ditions is almost a decade old,10 suggesting a need for more 
updated recommendations, similar to neuropsychological 
assessment in epilepsy surgery.20 Of note, >80% of respon-
dents noted that creating such recommendations should be a 
priority of the ILAE Psychology Task Force.
Approximately three quarters of respondents reported 
that their PWE, who had problems with depression or anxi-
ety, had accessed psychotropic medications or psychological 
treatment with a mental health professional at some point in 
their lifetime. There was also high endorsement of chang-
ing ASMs to manage depression (75%) and slightly less for 
anxiety (66%). These findings are moderately encouraging 
as neurologists/epileptologists can play a critical role in se-
lecting treatment strategies that take account of mental health 
comorbidities by adjusting ASMs known to exacerbate psy-
chiatric symptoms.10 However, the field appears to continue 
to favor medication adjustments over psychological therapies 
despite evidence that psychological therapies can be effec-
tive.34 Notably, there were several commonly endorsed bar-
riers to psychological treatments with over half the sample 
reporting a lack of appropriately trained mental health spe-
cialists, accessibility difficulties, and patients not wanting 
psychological/psychotropic treatment. Tackling these barri-
ers is of particular relevance to the ILAE Psychology Task 
Force, and some potential solutions are explored.
The findings strongly suggest more efforts are needed 
to identify and train mental health specialists to work with 
PWE, including the creation of registries of mental health 
professionals specializing in epilepsy, improving epilepsy re-
sources and educational opportunities for mental health pro-
fessionals and vice versa. One solution is the improvement of 
neurology and psychiatry residency programs with expanded 
curricula covering neurologic aspects of psychiatric disorders 
and vice versa to reduce this competency-related barrier.13 In 
relation to psychologists, there has also been recognition that 
some specialist training may be needed for the optimal deliv-
ery and tailoring of psychological interventions for PWE.35–
37 For instance, it has been recommended that mental health 
professionals, especially those working in medical settings, 
should have basic knowledge about epilepsy and psycholog-
ical interventions should ideally be implemented by profes-
sionals in direct contact with the medical epilepsy specialists 
treating the patients.10,34 In addition, it is recommended that 
psychological interventions are modified to accommodate 
common cognitive difficulties common in PWE,37 including 
the use of written handouts.
The integration of mental health specialists (eg, psy-
chologists, psychiatrists, qualified therapists, and social 
workers) within epilepsy care settings,14,34 which is, un-
fortunately, not currently common practice33 would solve 
many of the barriers revealed in the current study. Many 
other chronic health teams have implemented more inte-
grated care models for decades, where patients are offered 
psychological treatments by a psychologist, including 
HIV,38 chronic pain,39 and cancer.40 Psycho-oncology is 







Treatment options patients have 
accesseda 
392 392
Psychological treatment with a 
mental health professional
313 (79.8) 307 (78.3)
Psychotropic medications 313 (79.8) 293 (74.7)
Antiepileptic medication changes 294 (75) 260 (66.3)
Psychoeducation 170 (43.4) 173 (44.1)
Advocacy / self-help groups 100 (25.5) 92 (23.5)
Information brochures 90 (23) 98 (25)
None 10 (2.6) 15 (3.8)
Barriers to psychological treatment 
for depression/anxietya 
390
Lack of appropriately trained 
mental health specialists
234 (60)
Patients cannot access 
psychological treatment (eg, 
costs, travel restrictions)
204 (52.3)
Patients do not want 




difficulties limit the benefits of 
psychological treatment
160 (41)
Difficulties identifying when 
to refer PWE to psychological 
treatment
101 (25.9)




Therapist fears of patients having 
seizures in session
68 (17.4)
Psychological treatments (eg, 




aResponses were not mutually exclusive, and participants could select more than 
one. 
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now a required subspeciality of oncology dedicated to as-
sisting patients manage the psychosocial(-spiritual) impact 
of cancer,41 which is critical to patient health outcomes. 
However, neurology is lagging behind this integrated model 
of care,42 which could help address treatment gaps for 
mental health comorbidities and work to improve overall 
self-management and quality of life of PWE.43,44. Another 
benefit of integrated care is that it is often more attractive 
to patients and family members who are concerned with 
the stigma associated with mental healthcare services45 and 
accessibility issues. An excellent example of an integrative 
care model in an outpatient pediatric epilepsy center in the 
United States is outlined by Guilfoyle and colleagues.46,47 
This service involves all children with epilepsy being seen 
by a pediatric psychologist during routine epilepsy visits 
soon after diagnosis, with screening of mental health co-
morbidities occurring every six months. This preventative 
and proactive model ensures timely screening and refer-
rals for outpatient treatment to prevent the exacerbation of 
symptoms. This service has been found to be highly ac-
ceptable to patients and did not add to overall healthcare 
charges related to improving patients’ quality of life.48,49
Over the past decade, there have been significant develop-
ments in the remote delivery of psychological treatments via 
the Internet, videoconferencing, and telephone as a way of 
overcoming accessibility difficulties to psychological treat-
ments. There is now substantial evidence for the effectiveness 
and acceptability of these interventions for common mental 
health50,51 and some physical health conditions.52,53 Several 
trials of remotely delivered interventions to improve mental 
health outcomes in PWE have yielded very encouraging re-
sults,54–56 and these treatments can be optimized for people 
with cognitive difficulties.54,57
This study has several limitations, including online sur-
vey administration, which likely yielded lower participation 
rates (<10%) for countries who have lower resources and poor 
Internet access. While online survey administration was prac-
tical, relatively accessible and time and cost-efficient, study 
findings are likely biased toward more middle- to high-income 
countries and health systems. Several countries were also rep-
resented by only a single participant (eg, Japan, Uganda), 
which may have introduced some bias. The survey was also 
written in English, which may have also presented as a barrier 
to some international respondents. Furthermore, it is possible 
that some people and ILAE chapters have reached an “on-
line survey fatigue” with requests for these types of studies 
growing in popularity over recent years. This may explain the 
lower response rate to this survey compared with other ILAE-
promoted surveys.58 However, it should be noted that the cur-
rent number of responders is higher than previous surveys 
in the area of mental health comorbidity.33 Thus, the lower 
response rate may instead reflect less interest in this subject 
area. Respondents also worked across varying health systems, 
which may have very different funding and organizational pro-
cesses, particularly in lower income countries. Unfortunately, 
it was not possible to perform detailed comparisons between 
low/middle- and high-income countries on most of the mul-
tiple response data collected. It is also not clear whether our 
findings differed between those working in adult versus pedi-
atric epilepsy health settings. Finally, the survey also failed to 
assess types and intensity of psychological treatments PWE 
had accessed or access to social workers and occupational 
therapists who often provide mental health care. Given the 
survey was mainly promoted through the ILAE networks, it is 
not surprising that most respondents had a special interest in 
epilepsy. Furthermore, it is likely that those who did respond 
also had a special interest in mental health comorbidity, and 
the results may be biased toward professionals who believe 
this is an important area and therefore have more favorable 
management and procedures in place.
5 |  CONCLUSIONS
This study highlighted the ongoing underserved diagnos-
tic and treatment needs for mental health comorbidities in 
PWE, underscoring that less than half of respondents felt ad-
equately resourced to manage depression and anxiety in their 
patients. The results identify a number of important areas for 
improvement, including the need for updated protocols to 
help guide epilepsy services on how to best manage men-
tal health comorbidities in PWE and for training/education 
of more mental health professionals in the area of epilepsy 
and more epilepsy providers in mental health screening and 
management. It also highlights the value of including mental 
health professionals on epilepsy teams and integrated care 
models for psychological care, particularly those involving 
remote treatment options. While the importance of manag-
ing mental health aspects of epilepsy appears to be well rec-
ognized by epilepsy community clinicians, much more work 
on management and implementation of mental health care 
is needed to provide care for PWE. These findings have in-
formed the priorities of the ILAE Psychology Task Force by 
identifying practice and education gaps.
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